Enanta Pharmaceuticals | ENTA - Market Capitalization


Enanta Pharmaceuticals reported $213.3M in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 508.97B 46.71B Nov/2026
Amgen USD 247.94B 20.06B Nov/2026
Anika Therapeutics USD 139M 3M Dec/2025
Arrowhead Research USD 11.5B 2.72B Jun/2026
AstraZeneca USD 213.88B 23.43B Nov/2026
BioCryst Pharmaceuticals USD 2.54B 880M Jun/2026
Biogen USD 33.38B 1.48B Sep/2026
Bristol-Myers Squibb USD 127.46B 9.81B Sep/2026
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Gilead Sciences USD 184.82B 27.96B Sep/2026
GlaxoSmithKline GBP 74.11B 6.03B Sep/2026
Halozyme Therapeutics USD 15.62B 3.09B Nov/2026
Heron Therapeutics USD 238M 7M Dec/2025
Immunic USD 64M 23M Dec/2025
Incyte USD 24.6B 1.95B Sep/2026
Insmed USD 24.93B 1.82B Sep/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
J&J USD 653.61B 42.25B Sep/2026
Karyopharm Therapeutics USD 126M 9M Mar/2026
Ligand Pharmaceuticals USD 6.23B 108M Sep/2026
Merck USD 375.59B 17.09B Nov/2026
Neurocrine Biosciences USD 14.46B 45M Nov/2026
Novartis USD 292.09B 51.5B Sep/2026
Novavax USD 1.09B 316M Dec/2025
Pfizer USD 169.88B 6.47B Nov/2026
Roche Holding CHF 270B 3.66B Jun/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
Vertex Pharmaceuticals USD 142.88B 10.37B Nov/2026